by Jordana Choucair | Feb 4, 2022 | Life Sciences
Eli Lilly and Co. pushed back its timeline to ask regulators to grant accelerated approval to its experimental Alzheimer’s disease drug. The drugmakers said approval would have little impact on its business this year given Medicare officials’ decision to...
by Jordana Choucair | Feb 3, 2022 | Life Sciences
Merck & Co. said it expects its sales to surge by up to 18 percent in 2022 compared with last year, primarily driven by demand for the COVID-19 antiviral pill molnupiravir. Merck said sales of the drug, which it developed with Ridgeback Biotherapeutics LP, reached...
by Jordana Choucair | Feb 2, 2022 | Life Sciences
Moderna Inc. began testing an experimental HIV vaccine based on its mRNA technology. The company plans to monitor 56 HIV-negative adults in the U.S. for six months in the Phase 1 clinical trial. Previous efforts to develop HIV vaccines have failed, and the illness...
by Jordana Choucair | Feb 1, 2022 | Life Sciences
The Department of Justice (DOJ) announced that Cardinal Health will pay $13.1 million to settle allegations that it paid kickbacks to physicians to get them to purchase specialty drugs through Cardinal. According to the DOJ, the wholesale distributor gave doctors...
by Jordana Choucair | Feb 1, 2022 | Life Sciences
Pfizer and BioNTech are expected to soon ask the FDA to grant an emergency use authorization for their two-dose vaccine that can be administered to children under the age of five. According to sources familiar with the matter, the FDA urged the companies to submit...
by Jordana Choucair | Feb 1, 2022 | Life Sciences
The FDA granted Moderna’s COVID-19 vaccine full approval for use in people aged 18 and older. The vaccine, named Spikevax, is the second COVID-19 vaccine to receive full approval from the FDA, behind Pfizer’s Comirnaty vaccine. There’s no difference between the...
Recent Comments